Thierry Facon, MD, Professor of Hematology at Lille University Hospital in France, discusses 5-year follow-up data from the MAIA study evaluated the addition of daratumumab to the standard of care with lenalidomide and dexamethasone in multiple myeloma patients. The data was presented at the EHA 2021 Virtual Congress.
Multiple myeloma is a blood cancer associated with uncontrolled growth of plasma cells. While the disease is treatable, relapses are common and some patients are refractory to first line treatment.
At EHA 2021, Dr. Facon presented the prespecified interim analysis for overall survival. In this analysis, it was found that after a median follow-up of nearly five years (56 months), a 32% reduction in the risk of death was observed in the daratumumab + lenalidomide + dexamethasone treatment arm vs. lenalidomide + dexamethasone arm. Median progressive free survival (PFS) was not reached with daratumumab + lenalidomide + dexamethasone treatment arm (though Dr. Facon believes it will be reached around 60 months) while median PFS was reached at 34.4 months with the lenalidomide + dexamethasone treatment arm. The estimated five-year PFS rate is 52.5% with daratumumab + lenalidomide + dexamethasone compared to 29% with lenalidomide + dexamethasone. Median overall survival (OS) was not reached in either arm and the estimated five-year OS rate is 66% with daratumumab + lenalidomide + dexamethasone group compared to 53% with teh lenalidomide + dexamethasone group.
No additional adverse events nor any new safety concerns were identified. The most common adverse events include neutropenia, pneumonia, anemia, and lymphopenia.
To learn more about multiple myeloma, visit our Multiple Myeloma Learning Page.